ASHG 2008 Kicks off

Last night the American Society of Human Genetics meeting started in Philadelphia and kicked off with a crowded mixer featuring classic Philly fare (hoagies and pretzels). I asked Aravinda Chakravarti what he thought the major themes of the meeting would be. He said he was glad to report that the field has moved slightly away from data to new ideas. New ideas including better understanding of the genetic structure of disease and the characterization and understanding of the meaning of structure in the genome, including copy number variations (a term that appears in the abstract book more than 200 times). That’s not to say that data have taken a back seat. It’s no secret that the data are pouring out from new sequencing technologies. Illumina staged a brief press conference featuring the three papers appearing last week in Nature that presented four new full human genome sequences, those of an Asian individual, an African individual and one from a woman and from the cancer that she eventually died from.

Stay tuned for most posts from the field, and possibly some guest posts.

A chilling end to SDB 2008

Harry Eastlack looked like any other baby when he was born in Philadelphia in 1933, save for an inward-turned big toe, but at age ten, he developed a swelling and stiffness in his neck and back. The group of Philadelphia doctors that treated Harry would soon discover that the soft tissues of his body including muscles and cartilage were slowly, painfully transforming into bone, twisting and fusing the young man’s body until his death at age 40. His plight is known as fibrodysplasia ossificans progressiva (FOP), and it’s caused by an autosomal dominant mutation, usually arising de novo in 2 out of every million people. In the last talk at the 2008 Society for Developmental Biology meeting in Philadelphia, Eileen Shore from the University of Pennsylvania School of Medicine talked about her work from bedside to bench with children with FOP.

After a long search over many years for a handful of families who have passed on the trait across generations, she and a group of researchers were able to link the disease to a single base substitution in a gene for a bone morphogenetic protein type I receptor called ACVR1 in 2006. In the years since, Shore and a group of collaborators has worked to define how this tiny mutation could cause such a devastating disease. In cell culture, in zebrafish, and biochemically, a picture began to emerge of a pathway that is not completely turned on but is very sensitive to a ligand. Recently Shore and colleagues have had success in engineering a mouse with the mutant gene knocked in. Though they haven’t finished developing the line, chimeras containing both the mutant gene cells and normal mouse cells have a similar inward turned big toe on their feet and are beginning to show signs of bone formation in soft tissues. Hopefully, using these chimeras, her group will be able to breed a pure line of mice with the disorder in which drugs to treat the disease can be screened and tested.

It was a stirring story and a great preparatory talk leading up to the meeting’s closing celebration at Philadelphia’s hallowed Mutter Museum at the College of Physicians of Philadelphia. Harry Eastlack decided at age 20 that he would donate his skeleton to advance research on the disease that plagued his life, and it is a centrepiece to the Mutter’s amazing exhibits. See pictures here. They’re a chilling reminder of what can happen when development goes awry.

Testes all over at SDB 2008

I once had an English teacher who gave copious quizzes. Once, when someone complained about the work, he replied, “If you think my quizzes are bad you should see my testes.” It was an all-boys Catholic school, which explains how he could get away wish such crude sentiments. Nevertheless, I saw a talk about an organism that would put him and his abundant quizzes to the shame he deserves. The planarian, a flat, freshwater dwelling worm with comical eyespots and a superlative reputation for regeneration has another surprise under its belt. In addition to two ovaries just south of its tiny brain, the sexual form of some planarians has dozens of testes spread throughout its body. These are hardly exempt from the famous regenerative qualities of the planaria which can regenerate from just a tiny portion, but they grow back in ways that were interesting to the attendees at this morning’s talk on stem cells and development. Philip Newmark of the University of Illinois at Urbana-Champaign showed how when you decapitate a planarian, the testes in the body disappear as the head regrows, only once the whole animal is intact does it resume it’s production of sperm. And when starved the animals resorb the plentiful sex organs until the food returns. When Newmark’s group fed the worms bacteria engineered to produce short interfering RNAs for a specific gene called nanos, they were able to block the testes regeneration even though the animal developed fine and had no obvious defects, looking somewhat like their asexual counterparts. They’re using this model to find other genes that might be important in testes regeneration and development.

Mmmm, pie at SDB 2008

In a stem cell development talk this moring, Haifan Lin, director of the Yale Stem Cell Center showed a picture of a pie he had decorated with the letters R-N-A. What was he celebrating? Something that quite frankly frightens me.

His group has been investigating piRNAs. These are short strands of RNA, generally 30 nucleotides long in mice and a little bit shorter in Drosophila. These are similar in some ways to microRNAs and short interfering RNAs (siRNAs), but the name piRNA (literally pronounced “Pie-R-N-A”) comes from the fact that they interact with a protein called PIWI. They’re found in abundance in the testes of mice and flies and appear not only to stifle gene expression by interacting with PIWI and corresponding DNA sequences (similar to other short RNAs) but also to stabilize and promote expression (possibly similar to other short RNAs as well). Just distinguishing these elements from other short RNAs is tricky enough. The janus-like nature of piRNAs could make for a real headache. What dictates whether they turn things on or off? Then there’s abundance. Studies have counted as many as 50,000, and Lin estimates that there are as many as four times that amount. When he realilzed how long that would keep his lab busy, Lin brought in some RNA pie to celebrate (the picture looked like apple). Still he’s not completely comfortable with all the implications of his work. The testes produce thousands of different piRNAs all coming from DNA that was formerly considered junk. “Does that make the testis a genetic junkyard?” Lin asked. He quipped: “At least emotionally I have a problem with that.”

Turtle power at SDB 2008

At last night’s poster session I met Scott Gilbert of Swarthmore College and editor of a definitive text on Developmental Biology. He told me that before his last invited talk, at a symposium honouring the retirement of his former mentor, most in attendance wondered what turtleshell was all about. The scientists, figuring the title of his talk referred to some wacky Drosophila gene name, were surprised to find that Gilbert actually works on turtle shell development. Here he is with colleague Judith Cebra-Thomas at last evening’s poster session.

Gilbert.jpg

Gilbert and his colleagues have found that the bones that make up a turtle’s upper and lower shells develop by a bone development program called “intramembranous ossification” much like skull bones. They do their studies in the red-eared slider, a common pet-shop favourite. Controversially, they’ve proposed that the shell develops from neural crest cells that migrate out from the neural tube after it closes. They injected a dye into the neural tube of turtle embryos and find them in the carapacial ridge (what will become the top shell of the turtle). They believe these cells then migrate to help form the bottom shell.

I had to get a shot of their spiffy turtle shirts. I mentioned that they might not want their poster data showing up in the picture as I’d want to put it on the internet. But they waved off those concerns saying they weren’t worried about being scooped. OK, there probably isn’t a whole lot of competition in this field. Besides, I like to think they’ve taken their Aesop seriously.

Before the rain at SDB 2008

Just before a violent downpour at Philadelphia’s UPenn campus, I got to chat with Society for Developmental Biology president Eric Wieschaus of Princeton University. (An aside: His quirky sense of humour set a nice tone at the opening symposium last night. When the powerpoint presentation he was working off of broke down, he admitted “My lab doesn’t let me get too close to machines.” Later clarifying: “I’m allowed near the microscopes, just not the ones with moving parts.”). He told me he didn’t quite have the clarity of thought to offer me any overarching trends in development in general or at the meeting in particular. Indeed having been to a symposium this morning that dealt with a different organism for nearly each speaker (Amphioxus, Arabidopsis, Ascidian, Bat, Cardamine, Lamprey, Mouse, Nematode and Zebrafish, oh my!), it can be hard to pick out trends. Wieschaus was nonetheless chuffed about the quality of the talks, and the locale. Passing on the usual route of using a conference centre meant a smaller meeting for SDB. Costs for attendees may be a bit lower (student housing is available, but I’ve heard some groans about the amenities), but Weischaus says the costs for the Society end up being about the same. Ultimately it was the connection with the University of Pennsylvania community that the organizers wanted to achieve. And I’ll admit the site has quite a bit more character and charm than the sterile Pennsylvania Convention Center. Still it’s strange to have posters split between three different tiny meeting rooms on two different floors. As far as attendance, Weischaus said the site was comparable to Cancun, where the conference was held last year. As I looked to the darkening sky and reminded Weischaus that we were nearly 100 miles from the beach, he pulled back. “Well it’s less than we could fit at San Francisco.” About 750 to 800 are in attendance. I hope the rest managed to stay dryer than I did.

At SDB 2008: the same, but different

Most have abandoned Haeckel’s old chestnut that ontogeny recapitulates phylogeny, but when two organisms actually appear to have identical embryonic development, how close are the genetic programs that underlie each. In a wide ranging symposium on evolutionary genetics at the Society for Developmental Biology 67th annual meeting, Itai Yanai from Craig Hunter’s lab at Harvard looked at two nematode worms that are practically indistinguishable, the lab workhorse Caenorhabditis elegans and Caenorhabditis briggsae from which it diverged some 80 to 100 million years ago. Evolutionarily, that puts them about as distant as humans and mice, but morphologically they’re practically indistinguishable. So, what can Yanai say about how these organisms use those different genes during what he calls the “200 most exciting minutes in the life of the worm”? This is the time in which the worm goes from four cells to 190, and genes are turned on and off in what one would assume is a tightly controlled regulatory regimen program. Yanai constructed microarrays to look at gene expression in the two species of worm. Specifically he looked at expression of genes that are so-called one-to-one orthologs (meaning the genes look a lot alike in both organisms and haven’t been duplicated in either species since they diverged).

There are about 12,000 orthologs, and 3,500 of these gave a good profile. Of these, roughly a quarter of the genes are highly divergent in their expression. To see that much divergence during this crucial developmental period was sort of shocking, but Yanai presents some potential explanations. Shuffling of the genome, for example, could put a gene necessary for development next to one not really needed at the time. So, less necessary genes go along for the ride. It serves as a reminder that gene expression is a very rough tool for extrapolating function. Yanai noted that there’s actually quite a lot of variability in expression for different strains of C. elegans. Someone in the audience asked if that means that there’s considerable flexibility and tolerance for misexpression during development, such that there may be no canonical set of genes required. Yanai answered that to the contrary, such comparative work may help to whittle down to those genes that really are necessary. He plans to continue study in two related species of the frog Xenopus.

At Society of Developmental Biology 2008: “What the heck is a YFome?”

The opening symposium for the 67th annual Society of Developmental Biology meeting was held in the Irvine Hall on the University of Pennsylvania campus in Philadelphia. The cavernous auditorium is quite ornate with a massive pipe organ lining the front wall and arresting décor and proportions. Still more arresting was a word several slides into a talk on development and genomics by Joseph Ecker of The Salk Institue. He presented a list of ‘ome words like Proteome (cataloguing proteins), Promoterome (developing lists of DNA promoters), Phenome (cataloguing of phenotypes), Orfeome (catalogue of open reading frames), and more. But several in the hall were mumbling “What the heck is a YFome?” Before moving on to the next slide, Ecker shed some light on the mystery. Since someone invariably accuses him of missing some area of study he said, he added “Your Favourite ‘Ome.”

ISSCR 2008: It’s “Shinyamania”

I cornered Harvard’s George Daley shortly after this afternoon’s opening symposium at the International Society for Stem Cell Research meeting in Philadelphia, and asked him for some stats and trends at the meeting. He’s the current president of ISSCR. There are 24,000 2,400 pre-registered attendees, he told me. That’s only 24 2.4 times the size of the last meeting I attended. As for trends: “There’s certainly a bit of Shinya-mania,” Daley said. He was referring to the focus on induced pluripotent stem cells (iPS cells), adult human cells reprogrammed to a stem cell-like state thanks to a couple of transcription factors by a Japanese group led by Shinya Yamanaka.

**Note updated numbers. It was a big meeting, but not that big! 24,000 would be getting into society for neuroscience range!

Daley wasn’t kidding. Cruising the poster session this evening, I was intrigued by the dense clump of bodies congregating around a handful of posters in one corner of the exhibit hall. All of them had to do with using variations on the so-called “Yamanaka factors.” Yamanaka used four, but there was a poster talking about using just two (Oct4 and Klf4) on adult neural stem cells with high efficiency. The work, presented by Vania Broccoli of San Raffaele Scientific Institute was drawing a crowd. Next to him Mali Prashant of Johns Hopkins was presenting data on reprogramming using non-integrating lentiviral vectors. John Dimos from Harvard was presenting work on developing models of the neurodegenerative diseases spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) respectively in embryonic stem cells (retrieved from discarded embryos that had been diagnosed as carrying SMA associated mutations), and – you guessed it – induced pluripotent stem cells derived from the cells of adults with ALS. According to the poster, the SMA cells have a distinct phenotype with low numbers of motor neurons compared to other ES cell cultures that can be rescued genetically. The ALS cells are still being worked on. Dimos’ PI, Kevin Eggan, has been trying to do the same work modeling ALS through stem cell cloning, essentially dropping a nucleus into an egg and deriving embryonic stem cells from the resulting embryo. But eggs have been scarce.

ISSCR 2008: Making Beta Cells (and cutting out the middleman)

Harvard’s Doug Melton, in a plenary talk this afternoon to open the International Society for Stem Cell Research (ISSCR) meeting in Philadelphia, actually didn’t talk about stem cells at all. Rather he discussed new results showing direct differentiation of pancreatic tissue into the elusive and important Beta cells, skipping stem cells altogether.

It was clear from the opening session, that a large part of the conference would focus not on the derivation of stem cells, but rather their re-differentation into useful tissues, which is not so easy as one might think. Take the beta cell for example. Melton has had a long-standing project to derive beta cells from es cells. The potential is obvious. For folks with type 1 diabetes, beta cells can be transplanted with limited success, but are currently in short supply (cells from two cadavers are required for the so-called Edmonton protocol).

After four years of work trying to use chemical compounds to edge stem cells down the developmental path of the insulin producing beta cells, he found two with 70% efficiency in moving the cells the very first step in a process that looks to contain maybe six. So, his group began experiments to short circuit the process. Rather than taking an undifferentiated stem cell, could one take a fully developed adult cell and switch its fate using transcription factors without reverting to stem cells? The answer, ostensibly seems to be yes. Screening for upwards of 1000 factors in 5000 mouse embryonic tissue samples, Melton’s lab identified 28 factors that appeared closely related to beta cell differentiation formation. Paring down brought the number to nine. Using a virus to inject the genes that encode these transcription factors into the pancreas of living mice, they were able to cause exocrine cells in the pancreas to start producing insulin and look just like beta cells in every way they’ve looked. Melton says, it’s “not the case that they’ve just turned on the insulin genes. There’s a panoply of genes turned on and off in response to these transcription factors.” They even started producing VEGF and promoting angiogenesis to get blood supply. The group has been able to reliably convert cells to insulin producing beta cells using just three of the nine genes: Ngn3, Pdx1, and Mafa. Mice in which islets had been chemically ablated achieved some level of blood sugar control, but not that of wild type. And despite waning expression of the three genes they injected, the phenotype of the transformed cells remained for several months. Melton says he wouldn’t necessarily predict a gene therapy approach based on his findings, but if in vitro technologies could be adapted, they might increase the number of beta cells for transplant operations. This type of cellular reprogramming involved here is fascinating. I remember when few believed de-differentiation from adult cells to pluripotent stem cells was possible with out the help of egg cytoplasm. iPS cells proved that wrong. This fate-jumping reprogramming without intervening de-differentiation is even more astonishing.